Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
IRWD Ironwood Pharmaceuticals
- 0.8787
- +0.1042+13.45%
Close Apr 24 16:00 ET
- 0.8802
- +0.0015+0.17%
Post 16:54 ET
142.18MMarket Cap87.87P/E (TTM)
0.8900High0.7501Low2.98MVolume0.7786Open0.7745Pre Close2.50MTurnover2.41%Turnover Ratio87.87P/E (Static)161.81MShares8.450052wk High-0.47P/B108.64MFloat Cap0.591052wk Low--Dividend TTM123.64MShs Float21.2000Historical High--Div YieldTTM18.06%Amplitude0.5910Historical Low0.8390Avg Price1Lot Size
Ironwood Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -20.63%351.41M | -22.98%90.55M | -19.47%91.59M | -12.09%94.4M | -28.05%74.88M | 7.83%442.74M | 9.66%117.55M | 4.70%113.74M | 10.44%107.38M | 6.70%104.06M |
| Operating revenue | -20.63%351.41M | -22.98%90.55M | -19.47%91.59M | -12.09%94.4M | -28.05%74.88M | 7.83%442.74M | 9.66%117.55M | 4.70%113.74M | 10.44%107.38M | 6.70%104.06M |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -6.82%255.69M | -20.66%58.98M | -4.48%65.94M | -22.64%67.35M | 44.25%63.42M | 71.22%274.4M | 91.43%74.34M | 71.87%69.03M | 109.40%87.06M | 10.79%43.96M |
| Selling and administrative expenses | -8.87%144.27M | -13.13%33.59M | 0.19%36.11M | -29.57%36.96M | 20.85%37.61M | 36.48%158.31M | 36.20%38.67M | 25.95%36.05M | 74.23%52.48M | 7.82%31.12M |
| Research and development costs | -4.02%111.42M | -28.83%25.39M | -9.57%29.83M | -12.11%30.39M | 100.94%25.82M | 162.25%116.09M | 241.53%35.68M | 185.71%32.99M | 201.93%34.58M | 18.71%12.85M |
| Operating profit | -43.14%95.72M | -26.95%31.56M | -42.62%25.65M | 33.08%27.04M | -80.94%11.46M | -32.76%168.34M | -36.79%43.21M | -34.71%44.71M | -63.49%20.32M | 3.89%60.1M |
| Net non-operating interest income expense | -974.72%-28.57M | -12.55%-8.14M | -2.18%-8.27M | -188.20%-6.1M | -205.52%-6.06M | -239.67%-2.66M | -284.41%-7.23M | -730.63%-8.09M | 681.75%6.92M | 372.15%5.75M |
| Non-operating interest income | -76.45%4.47M | -34.84%778K | -34.10%1.15M | -84.37%1.37M | -83.92%1.17M | 99.67%18.97M | -78.08%1.19M | -37.73%1.75M | 760.22%8.76M | 3,061.74%7.27M |
| Non-operating interest expense | 52.73%33.03M | 5.83%8.91M | -4.27%9.42M | 305.98%7.47M | 506.49%6.82M | 184.67%21.63M | 182.75%8.42M | 774.58%9.84M | 8.81%1.84M | -37.64%1.13M |
| Total other finance cost | ---- | ---- | ---- | ---- | 1.49%408K | ---- | ---- | ---- | ---- | -25.14%402K |
| Other net income (expense) | 99.82%-1.95M | 110.09%567K | 99.66%-16K | 99.81%-2.07M | -2,400.00%-437K | -612,048.90%-1.11B | -31,127.78%-5.62M | -3,202.65%-4.69M | -161,935.24%-1.1B | -97.40%19K |
| Gain on sale of security | ---- | ---- | ---- | ---- | ---- | -89.56%19K | --0 | ---- | ---- | -97.40%19K |
| Special income (charges) | 99.77%-2.59M | 98.70%-73K | 99.66%-16K | 99.81%-2.07M | ---437K | ---1.11B | ---5.62M | ---4.69M | ---1.1B | --0 |
| -Less：Restructuring and merger&acquisition | -85.84%2.59M | -88.24%73K | -99.66%16K | -84.11%2.07M | --437K | --18.32M | --621K | --4.69M | --13.01M | --0 |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | --1.1B | --5M | ---- | --1.09B | ---- |
| Other non- operating income (expenses) | --640K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Income before tax | 106.88%65.2M | -20.97%24M | -45.61%17.37M | 101.75%18.88M | -92.47%4.96M | -475.59%-948.07M | -57.99%30.36M | -54.32%31.93M | -2,100.97%-1.08B | 16.64%65.86M |
| Income tax | -22.96%64.32M | -32.29%21.74M | -23.68%13.72M | 48.88%19.74M | -54.73%9.12M | 7.93%83.49M | 37.21%32.11M | -8.21%17.98M | -20.65%13.26M | 14.06%20.15M |
| Net income | 100.09%880K | 229.28%2.26M | -73.86%3.65M | 99.92%-860K | -109.10%-4.16M | -689.24%-1.03B | -103.57%-1.75M | -72.28%13.95M | -3,038.18%-1.09B | 17.82%45.71M |
| Net income continuous Operations | 100.09%880K | 229.28%2.26M | -73.86%3.65M | 99.92%-860K | -109.10%-4.16M | -689.24%-1.03B | -103.57%-1.75M | -72.28%13.95M | -3,038.18%-1.09B | 17.82%45.71M |
| Minority interest income | 0 | 0 | 0 | 0 | -29.32M | -658K | -1.37M | -27.29M | ||
| Net income attributable to the parent company | 100.09%880K | 307.54%2.26M | -76.20%3.65M | 99.92%-860K | -109.10%-4.16M | -672.50%-1B | -102.22%-1.09M | -69.55%15.32M | -2,964.58%-1.06B | 17.82%45.71M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 100.09%880K | 307.54%2.26M | -76.20%3.65M | 99.92%-860K | -109.10%-4.16M | -672.50%-1B | -102.22%-1.09M | -69.55%15.32M | -2,964.58%-1.06B | 17.82%45.71M |
| Basic earnings per share | 100.16%0.01 | 300.00%0.02 | -80.00%0.02 | 99.85%-0.01 | -110.00%-0.03 | -670.80%-6.45 | -103.13%-0.01 | -69.70%0.1 | -2,950.00%-6.84 | 20.00%0.3 |
| Diluted earnings per share | 100.16%0.01 | 300.00%0.02 | -77.78%0.02 | 99.85%-0.01 | -112.00%-0.03 | -771.88%-6.45 | -103.70%-0.01 | -67.86%0.09 | -3,357.14%-6.84 | 19.05%0.25 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now